Search Results
Found 7 results
510(k) Data Aggregation
(128 days)
Icare Finland Oy
The iCare ST500 tonometer is a device intended to be used for the intraocular pressure of the human eye.
The iCare ST500 tonometer is intended to be used by healthcare professionals.
The iCare ST500 tonometer is based on a patented, induction-based rebound method, which allows intraocular pressure (IOP) to be measured by a healthcare professional accurately, rapidly and without an anesthetic. The iCare ST500 tonometer measures a patient's IOP while he or she is in an upright (sitting) position. It is attached to a slit lamp with the ST500 Adapter, making it easy to use during a standard eye exam. This tonometer is designed only for use with a slit lamp not as a handheld device. The tonometer is compatible with most of the common slit lamp models on the market.
The tonometer system consists of the iCare ST500 tonometer (together with ST500 Remote and ST500 Adapter, ST500 SmartCradle and a medical power supply used with ST500 SmartCradle), and a compatible printer and slit lamp.
With the iCare rebound measurement method, a miniature, lightweight, single-use probe is launched in a direction perpendicular to the surface of the center of the cornea of the eye. The probe is composed of a medical grade plastic tip and a metal shaft. The metal shaft is magnetized prior to the measurement. During the measurement, the probe can be considered to act like a moving magnet that induces an electric signal in the surrounding coil allowing for a highly accurate measurement of the probe's motion. After launching. the probe briefly contacts the cornea and bounces back. The tonometer records multiple parameters covering the motion of the probe, including deceleration, and rebound time. Using a proprietary algorithm, the device can calculate the eye's IOP.
The displayed IOP reading is derived from the results from a sequence of six individual probe rebounds. The displayed IOP measurement is also stored in the tonometer's memory for later retrieval.
The iCare ST500 tonometer has a rechargeable battery and can be charged in the ST500 SmartCradle powered by a medical power supply. The tonometer can be operated by using the buttons on the tonometer or by using the wireless battery-operated ST500 Remote control.
Here's a breakdown of the acceptance criteria and study details for the iCare ST500 (TA04) tonometer, based on the provided FDA 510(k) summary:
1. Table of Acceptance Criteria and Reported Device Performance
Performance Metric | Acceptance Criteria (from ANSI Z80.10:2014) | Reported Device Performance |
---|---|---|
Bench Testing | ||
Accuracy | Met predetermined criteria | Met predetermined acceptance criteria for accuracy over the measurement range. |
Repeatability (Default) | Met predetermined criteria | Highest standard deviation was 0.44 mmHg (CV 1.1%). |
Repeatability (Quick Measure) | Met predetermined criteria | Highest standard deviation was 0.78 mmHg (CV 1.9%). |
Reproducibility (Default) | High reproducibility | Mean difference between operators: -0.12 mmHg. Standard deviation: 0.75 mmHg. R-squared: 99.8%. |
Reproducibility (Quick Measure) | High reproducibility | Mean difference between operators: -0.02 mmHg. Standard deviation: 0.91 mmHg. R-squared: 99.7%. |
Clinical Testing | ||
Correlation with GAT | Requirements of ANSI Z80.10-2014 | Average underestimation of IOP by 0.21 mmHg compared to GAT. |
Underestimation in low (0.20 mmHg) and medium (0.49 mmHg) IOP groups. | ||
Overestimation in medium (0.18 mmHg) IOP group. | ||
Regression analysis: slope 1.03, squared Pearson coefficient 0.89. | ||
Conclusion: Met the requirements of ANSI Z80.10-2014. | ||
Outliers (Clinical, ≤ 16 mmHg) | (Implicitly, low percentage) | 0.0% (0 out of 59 eyes) |
Outliers (Clinical, 16-23 mmHg) | (Implicitly, low percentage) | 3.5% (2 out of 57 eyes) |
Outliers (Clinical, ≥ 23 mmHg) | (Implicitly, low percentage) | 5.0% (2 out of 40 eyes) |
Overall Outliers (Clinical) | (Implicitly, low percentage) | 2.6% (4 out of 156 eyes) |
2. Sample Size Used for the Test Set and Data Provenance
- Clinical Test Set Sample Size: 156 eligible eyes from 165 enrolled subjects. In cases where both eyes were eligible, the eye with the higher GAT reference pressure was used for analysis.
- Data Provenance: Not explicitly stated from which country the data originated. It mentions "subjects having an appointment to the investigational site and from subjects recruited using a study announcement," implying a prospective study conducted at one or more clinical sites, likely in Finland where the applicant is based.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
- The document implies that Goldmann Applanation Tonometer (GAT) measurements were used as the reference standard (ground truth) in the clinical study. It does not specify the number of expert ophthalmologists or optometrists who performed the GAT measurements, nor their detailed qualifications (e.g., years of experience). Healthcare professionals would typically perform GAT measurements.
4. Adjudication Method for the Test Set
- The document does not describe any specific adjudication method for the test set. Given that GAT is considered a clinical gold standard, it's possible that a single GAT measurement was taken as truth, or if multiple readings were taken, the average was used without formal adjudication by additional experts.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
- No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done concerning AI assistance. This device is a tonometer with an AI-like algorithm for IOP calculation, but the focus of the clinical study was on its standalone accuracy against an established reference (GAT), not on human reader improvement with or without AI assistance. The "AI" here refers to the proprietary algorithm used to calculate IOP from probe motion, not a diagnostic AI system assisting human interpretation.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- Yes, a standalone performance study was done for the iCare ST500 tonometer. The clinical study compares the device's measurements directly to GAT, indicating its standalone performance without human interpretation or adjustment of the device's numerical output. The "algorithm only" aspect is embedded within the device's functionality to calculate IOP.
7. The Type of Ground Truth Used
- Clinical Ground Truth: Goldmann Applanation Tonometer (GAT) measurements. GAT is widely considered the clinical gold standard for intraocular pressure measurement.
8. The Sample Size for the Training Set
- The document does not provide information about a separate training set or its sample size. The device uses a "proprietary algorithm" to calculate IOP, but details on how this algorithm was developed, trained, or validated (if machine learning was used) are not disclosed in this summary. The provided clinical and bench testing data refer to the validation of the finalized device.
9. How the Ground Truth for the Training Set Was Established
- As the document does not mention a specific training set, it does not provide details on how ground truth for such a set would have been established. If the proprietary algorithm involved machine learning, its training data and ground truth establishment would be a separate, undisclosed process. The current document focuses on the regulatory validation of the final product.
Ask a specific question about this device
(197 days)
Icare Finland Oy
The iCare IC200 tonometer is intended to be used for the measurement of intraocular pressure of the human eye.
The iCare IC200 tonometer (model TA031) is a hand-held, battery-operated device which measures intraocular pressure (IOP) without the need for topical anaesthesia by rebound tonometry. The tonometer is to be used by a healthcare professional. The tonometer uses the rebound method. A small and light, sterile, single-use probe makes brief contact with the eye. The device measures the deceleration of the probe and the rebound time and calculates the IOP from these parameters. Deceleration of the probe is slower at low IOP compared to high IOP. The measurement method, the IOP measurement algorithm and rebound technology (including disposable probe) are identical with the predicate device. iCare IC200 tonometer can obtain IOP measurements in all angles between horizontal and supine directions. External design has not been modified. The user interface menu has been updated to contain a Quick Measure mode. The new Quick Measure feature is used to measure patient's IOP with fewer rebound measurements and faster measurement cycle. Quick Measure takes two or three rebound measurements; two if both results are within 2 mmHg and third if the difference between the first two measurements is greater than 2 mmHg.
The provided document, a 510(k) Premarket Notification review for the iCare IC200 tonometer, outlines the acceptance criteria and the study performed to demonstrate substantial equivalence to a predicate device. This submission focuses on a new feature of the device, the "Quick Measure" mode, rather than the entire device itself, as the underlying technology remains the same as the predicate.
Here's a breakdown of the requested information based on the provided text:
Acceptance Criteria and Reported Device Performance
The acceptance criterion for the Quick Measure mode's performance is its ability to meet the performance goals of the ANSI Z80.10:2014 standard for ophthalmic tonometers, specifically regarding agreement with reference tonometers (GAT and Perkins) within ±5 mmHg. This is presented across different Intraocular Pressure (IOP) subgroups.
Table 1: Acceptance Criteria and Reported Device Performance for iCare IC200 Quick Measure Mode
Group (IOP Range) | Acceptance Criteria (Max % Outside ±5 mmHg vs. Reference) | Reported Performance (N Eyes: % Outside ±5 mmHg vs. GAT Reference - Sitting) | Reported Performance (N Eyes: % Outside ±5 mmHg vs. Perkins Reference - Supine) |
---|---|---|---|
Low (≤ 16 mmHg) | Not explicitly stated as a percentage, but implied to be low, as 0% achieved. | 44: 0.0 % | 44: 0.0 % |
Medium (> 16 to |
Ask a specific question about this device
(267 days)
Icare Finland Oy
The iCare HOME2 tonometer is a prescription device intended as an adjunct to the routine clinical monitoring of intraocular pressure (IOP) of adult patients.
The iCare HOME2 tonometer (model TA023) is a hand-held, battery operated device which measures intraocular pressure (IOP) without the need for topical anaesthesia by rebound tonometry. The tonometer is to be used by the patients themselves. The tonometer uses the rebound method. A small and light, sterile, single-use probe makes brief contact with the eye. The device measures the deceleration of the probe and the rebound time and calculates the IOP from these parameters. Deceleration of the probe is slower at low IOP compared to high IOP. The measurement method, the IOP measurement algorithm and rebound technology (including disposable probe) are identical with the predicate device. iCare HOME2 tonometer is a further developed version of iCare HOME tonometer. It features enhancements such as possibility to measure IOP in any angle between 0° and 90° (horizontal to supine patient position) and possibility for wireless measurement result transfer to mobile device or to PC. External design and user interface have been modified for better usability and ergonomics. The measurement data can be uploaded to iCare CLINIC for further analysis using either iCare EXPORT (desktop application) or iCare PATIENT2 (mobile application). iCare PATIENT2 is a mobile app intended for transferring eye pressure measurement data from the iCare tonometer to the iCare CLINIC cloud service or an external system. The app displays the eye pressure measurement results and helps in glaucoma management. It is indicated for use by healthcare professionals and patients. Measurement results can be transferred to iCare CLINIC with either through a Bluetooth connection or by connecting the USB C type connector to the device and mobile phone, depending on the user's mobile phone operating system.
The iCare HOME2 tonometer is intended as an adjunct to the routine clinical monitoring of intraocular pressure (IOP) of adult patients.
Here's an analysis of the acceptance criteria and the study proving the device meets them:
1. Table of Acceptance Criteria and Reported Device Performance
The FDA clearance document for iCare HOME2 (K211355) does not explicitly list "acceptance criteria" in a bulleted or numbered format with specific thresholds. However, based on the provided "Performance and Safety Data" and "Clinical Performance Testing" sections, we can infer the implied acceptance criteria were related to accuracy, repeatability, and reproducibility compared to existing tonometers, as well as safety.
The key performance metric presented is the agreement between the iCare HOME2 and a reference tonometer (iCare IC200).
Acceptance Criteria (Inferred from study design) | Reported Device Performance (iCare HOME2 vs. iCare IC200) |
---|---|
Accuracy and Agreement with Reference Tonometer (iCare IC200) | Overall (N=47 patients): |
- Mean paired difference (iCare HOME2 - iCare IC200): 0.55 mmHg
- Standard deviation of the difference: 2.69 mmHg
- 95% CI for Mean Difference: -0.86, -0.23 mmHg (Note: This range seems incorrectly transcribed in the original document as it does not align with the mean paired difference, it may be a typo. Usually, it would encompass the mean diff. Assuming the mean diff is correct.)
- 95% Limits of Agreement (LOA) for Mean Difference: -5.82, 4.72 mmHg (This indicates that 95% of the differences between the two devices fall within this range). |
| Repeatability (Variability of repeat measurements) | For each patient, variability (difference of repeat measurements) for all IOP ranges was ~7.9%. |
| Reproducibility (Agreement regardless of device, operator, or measurement angle) | Demonstrated high agreement with manometric pressure regardless of the device, operator, or the measurement angle (from bench testing). |
| Safety | No adverse events (including corneal abrasions) were recorded in the study population. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size: 47 patients.
- Data Provenance: Prospective clinical study performed at East West Eye Institute, CA 90013, USA. The patients were either diagnosed glaucoma patients or 'glaucoma suspects'.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts
The document does not explicitly state the number of experts used or their qualifications for establishing the ground truth. The ground truth was established by comparison to a "reference tonometer (iCare IC200)," which is a cleared medical device. While healthcare professionals (likely ophthalmologists or technicians) would have operated both devices during the clinical study, their role in establishing a "ground truth" (beyond operating the reference device) for each patient's IOP is not detailed. The iCare IC200 itself is considered a "reference" for comparison.
4. Adjudication Method for the Test Set
The document does not describe any specific adjudication method (e.g., 2+1, 3+1). It appears a direct comparison between the iCare HOME2 measurements and the iCare IC200 measurements was performed. A "random eye was selected as the study eye for each patient."
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
The study described is not a Multi-Reader Multi-Case (MRMC) comparative effectiveness study involving human readers with and without AI assistance.** This device is a tonometer, a measurement device, not an AI-powered diagnostic imaging tool that assists human readers.** Therefore, this question is not applicable to the submitted document.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done
The iCare HOME2 is a physical tonometer device that performs measurements. It has an "IOP measurement algorithm" that calculates IOP from probe deceleration and rebound time. The clinical study evaluated the performance of this device (which includes its internal algorithm) when used by patients (self-measurement) compared to a reference tonometer (likely operated by a healthcare professional). Therefore, in a sense, the measurement output itself is "standalone" from direct human interpretation of raw data, but it's a device measurement, not an AI algorithm assisting human interpretation.
7. The Type of Ground Truth Used
The ground truth for the clinical study was established by comparison to a legally marketed reference medical device: the iCare IC200 tonometer (cleared in K190316). In addition, bench testing used "manometrically controlled artificial cornea" for accuracy and reproducibility assessment, implying manometric pressure served as a higher-level ground truth in those tests. For the clinical study, the IC200 served as the comparative standard.
8. The Sample Size for the Training Set
The document does not provide information about a "training set" in the context of machine learning or AI. The iCare HOME2 tonometer uses a "rebound method" and an "IOP measurement algorithm," which are stated to be "identical with the predicate device." This suggests the core measurement algorithm was likely developed and validated prior to this submission (possibly with data from the predicate device iCare HOME), and this submission focuses on the safety and effectiveness of the new device iteration. No specific training set for a machine learning model is mentioned.
9. How the Ground Truth for the Training Set was Established
As no specific training set for an AI/machine learning model is mentioned for iCare HOME2, information on how its ground truth was established is not available in the provided document. The device's measurement principles are inherited from the predicate device.
Ask a specific question about this device
(27 days)
Icare Finland Oy
The Icare HOME tonometer is a prescription device intended as an adjunct to the routine clinical monitoring of intraocular pressure (IOP) of adult patients.
The Icare HOME tonometer is a home-use handheld, battery operated device that measures the intraocular pressure (IOP) without the need for topical anaesthesia. It is for prescription use only and to be used under the supervision of a healthcare professional. The device is intended to be used by patients at home.
The tonometer uses the rebound method. A small and light, sterile, single-use probe makes brief contact with the eye. The device measures the deceleration of the probe and the rebound time and calculates the IOP from these parameters. Deceleration of the probe is slower at low IOP compared to high IOP.
The measurement sequence includes six measurements. The probe moves to the cornea and back during every measurement. The tonometer stores information on every complete measurement sequence of six measurements. The stored information includes the calculated final IOP, time and date of the measurement, identification of the eye (right or left) and the quality level of the measurement (i.e. the standard deviation of the six individual measurements).
The measurement data can be uploaded to Icare CLINIC for further analysis using either Icare EXPORT (desktop application) or Icare PATIENT (mobile application). Icare CLINIC is a browser-based software designed for managing patient information and the IOP measurement data.
The provided text does not contain detailed information about specific acceptance criteria related to a performance study for the Icare HOME tonometer, nor does it describe a study that explicitly proves the device meets such criteria in terms of clinical accuracy or diagnostic performance. Instead, this document is a 510(k) summary for a premarket notification, focusing on demonstrating substantial equivalence to a predicate device.
The document highlights:
- Changes: The modifications are primarily related to software (Icare LINK replaced with Icare CLINIC, Icare EXPORT, and Icare PATIENT) and connectivity (added Android support). There are also minor changes to user interface sounds and product appearance.
- Performance and Safety Data: The document states that the device has been tested according to relevant FDA recognized consensus standards for electrical safety, ophthalmic instruments, usability, software lifecycle processes, and photobiological safety.
- No Clinical Studies: Crucially, it explicitly states: "No clinical studies were performed to test this device modification." This means there is no new clinical data presented here to establish performance metrics (like accuracy, sensitivity, specificity, etc.) against a ground truth in a clinical setting for this specific modification. The substantial equivalence is based on the argument that the technological changes do not raise new issues of safety or effectiveness, and therefore, the performance is assumed to be equivalent to the predicate device.
Given this, I cannot extract the detailed information requested in the prompt (acceptance criteria, reported device performance, sample size for test set, expert qualifications, adjudication method, MRMC study, standalone performance, type of ground truth, training set size, how training set ground truth was established) as this information is not present in the provided document for this specific 510(k) submission. The document focuses on demonstrating that the modified device is substantially equivalent to the predicate device without requiring new clinical performance data.
However, based on the general context of medical device regulatory submissions and the information provided, here's what can be inferred or stated regarding the lack of such information:
Information Requested | Details from the Document |
---|---|
1. Table of acceptance criteria and reported device performance | Not provided in this document. The document focuses on demonstrating substantial equivalence based on technical changes and compliance with general safety standards, not on new clinical performance metrics. The measurement range of the device is stated as 5-50 mmHg, but this is a characteristic, not a performance criterion against a ground truth. |
2. Sample size for the test set and data provenance | Not applicable/Not provided. No new clinical test set data is presented for this 510(k) submission, as it explicitly states, "No clinical studies were performed to test this device modification." The evaluation relies on the safety and effectiveness of the previously cleared predicate device and the assessment that the changes do not introduce new risks. |
3. Number of experts used to establish ground truth & qualifications | Not applicable/Not provided. As no new clinical studies were performed for this specific modification, there's no mention of experts establishing ground truth for a test set in this document. |
4. Adjudication method for the test set | Not applicable/Not provided. No new clinical studies were performed for this specific modification. |
5. MRMC comparative effectiveness study and effect size | Not applicable/Not provided. The document does not describe any MRMC studies or human-in-the-loop performance evaluations specifically for this device modification. The device is a tonometer, which directly measures IOP, and thus, comparative effectiveness with human readers (in the sense of image interpretation for AI) isn't directly relevant in the same way it would be for an AI-powered diagnostic imaging device. Its accuracy would typically be compared to a gold standard IOP measurement method. |
6. Standalone (algorithm only without human-in-the-loop) performance | Not explicitly detailed as a new study. While the tonometer itself operates standalone to measure IOP, the document does not present new standalone performance data (e.g., accuracy against a gold standard) for this modified device. The assertion of substantial equivalence implies that its standalone performance is considered equivalent to the predicate device, for which such data would have been provided in its original 510(k). |
7. Type of ground truth used | Not applicable/Not provided in this document for new studies. For IOP measurement devices, the ground truth for performance studies would typically be established by a well-calibrated reference tonometer (e.g., Goldmann Applanation Tonometer) or other validated methods, but this is referring to the original predicate device's clearance. |
8. Sample size for the training set | Not applicable. This device is hardware-based for IOP measurement and the modifications pertain to software for data management/connectivity and minor hardware appearance changes. There is no indication of a machine learning-based component that would require a "training set" in the traditional sense of AI algorithm development for classification or prediction from data within the scope of this 510(k) submission. Therefore, a training set is not pertinent to the changes described. |
9. How the ground truth for the training set was established | Not applicable. As there is no training set for a machine learning algorithm described in this 510(k) modification, this question is not relevant to the provided text. The device performs a direct physical measurement. The software changes concern data handling and connectivity, not interpretive AI. |
In summary, this 510(k) document is a "Special 510(k)" for a device modification, and the strategy is to demonstrate substantial equivalence to a predicate device without new clinical performance data, relying on the argument that the changes do not affect the fundamental safety and effectiveness of the IOP measurement.
Ask a specific question about this device
(335 days)
Icare Finland Oy
The Icare ic200 tonometer is intended to be used for the measurement of intraocular pressure of the human eye.
The Icare ic200 (TA031) tonometer is a hand-held, battery operated device, which measures intraocular pressure (IOP) without the need for topical anesthesia. The Icare ic200 tonometer measures the IOP by utilizing the rebound method, where a small (1.8 mm diameter), light (26.5 mg) probe makes brief contact with the eve. The Icare ic200 probes are sterile (gamma sterilized), single-use accessories of the device. All other accessories of the Icare ic200 are non-sterile and do not have direct patient contact.
Icare ic200 allows IOP measurement of patients in all positions between sitting position (direction of probe movement 0°) and supine position (direction of probe movement 90°).
Identical to the predicate device, the Icare ic200 (TA031) tonometer records the speed of the probe upon initiation of a measurement sequence. When the moving probe contacts the cornea, the probe decelerates at a rate which depends on the intraocular pressure. The tonometer measures the deceleration of the magnetized probe and the rebound time during contact with the eye and calculates the IOP from these parameters.
A single measurement sequence includes six measurements. After the six measurements are completed, the tonometer calculates the final IOP and the result is provided on the display. JOP measurement result can be transferred to printer or to a PC via Bluetooth® connection.
The measurement method, the IOP measurement algorithm and rebound technology (including sterile, single-use probe) of Icare ic200 are identical to the predicate device Icare ic100 (TA011, K153694).
Here's the information about the acceptance criteria and the study that proves the device meets them, based on the provided text:
Device: Icare ic200 Tonometer
1. Table of Acceptance Criteria and Reported Device Performance:
Acceptance Criteria (Bench Performance) | Reported Device Performance (Bench) | Acceptance Criteria (Clinical Performance - from ANSI Z80.10:2014) | Reported Device Performance (Clinical - compared to GAT) |
---|---|---|---|
Accuracy: ± 1.2 mmHg (IOP ≤ 20 mmHg) | Met criterion | Max allowed % outside ±5 mmHg: 5% (overall) | 1.3% (overall) |
Accuracy: ± 2.2 mmHg (IOP > 20 mmHg) | Met criterion | Max allowed % outside ±5 mmHg: 5% (IOP ≤ 16 mmHg) | 0.0% |
Coefficient of variation CV 99.7%) | R-squared > 99.7% | Max allowed % outside ±5 mmHg: 5% (IOP ≥ 23 mmHg) | 0.0% |
Mean difference from true manometric pressure: 99.5%) | Mean difference: 0.10 mmHg, SD: 0.98 mmHg, R-squared > 99.5% |
Note: The document explicitly states that the Icare ic200 met the predetermined acceptance criteria for accuracy and bias over the measurement range, ensuring substantial equivalence to the previously cleared Icare ic100 tonometer. While the exact numerical acceptance criteria for bench testing (beyond matching the predicate) are not fully detailed for all parameters, the reported performance indicates that they were met. For clinical performance, the ANSI Z80.10:2014 standard's criteria were used, and the device conformed to them.
2. Sample Size Used for the Test Set and Data Provenance:
-
Clinical Test Set:
- Sample Size: 152 eyes
- Data Provenance: Not explicitly stated (e.g., country of origin). The study was a "clinical study" and "performed as intended," implying prospective data collection for this submission.
-
Bench Test Set:
- Sample Size:
- Accuracy and bias: Not explicitly stated, but performed with a "simulated IOP model."
- Repeatability: 10 measurements were performed (with 3 different angles for the tonometer).
- Reproducibility: Two operators performed three measurements with three different ic200 units in each measurement setup, resulting in 162 measurements per operator.
- Data Provenance: Laboratory bench testing.
- Sample Size:
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:
-
Clinical Study: The ground truth was established by comparator devices:
- Goldmann Applanation Tonometer (GAT) for sitting position.
- Tonopen Avia and Perkins for supine position.
- No information is provided on the number or qualifications of the operators for these reference devices in the clinical study.
-
Bench Testing:
- The ground truth was established by a "manometrically controlled test cornea" (i.e., a physical reference standard).
- No human experts were involved in establishing the ground truth directly for this bench test.
4. Adjudication Method for the Test Set:
- Clinical Study: Not explicitly mentioned, but the comparison was against established reference devices (GAT, Tonopen Avia, Perkins) for IOP measurement. There's no indication of a separate expert adjudication process for the clinical data itself beyond direct measurement comparisons.
- Bench Testing: No adjudication method mentioned; the comparison was against a known manometric pressure.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance:
- No, an MRMC comparative effectiveness study was not done.
- This device is a tonometer, a measurement device, not an AI-assisted diagnostic tool that would typically involve human readers interpreting images with or without AI assistance. The study focused on the device's accuracy and performance compared to established tonometry methods.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done:
- Yes, a standalone performance assessment was conducted for the device's measurement algorithm. The device itself performs the IOP measurement and provides a numerical result without human interpretation of raw data. The bench testing (comparing to manometric pressure) and the clinical study (comparing to reference tonometers) are effectively standalone assessments of the device's measurement capabilities. The software calculates the IOP from probe speed during impact.
7. The Type of Ground Truth Used:
- For Bench Testing: Manometric pressure from a controlled test cornea.
- For Clinical Testing: Intraocular pressure measurements from legally marketed predicate and reference devices: Goldmann Applanation Tonometer (GAT), Tonopen Avia, and Perkins tonometer.
8. The Sample Size for the Training Set:
- Not Applicable / Not Provided. The document describes a 510(k) submission for a rebound tonometer, which uses a physical measurement (rebound method) and an "IOP measurement algorithm" that is stated to be identical to its predicate device. This typically implies a deterministic algorithm or one trained on historical data, but the document does not detail a specific "training set" in the context of machine learning. The focus is on verifying and validating the device's performance, not on a new algorithm's training.
9. How the Ground Truth for the Training Set Was Established:
- Not Applicable / Not Provided. As mentioned above, the concept of a "training set" and its ground truth is not detailed in this submission because it's for a traditional medical device's performance verification, not necessarily a machine learning model requiring a distinct training phase in the context of this document. The "IOP measurement algorithm" and rebound technology are identical to the predicate, suggesting it was established previously.
Ask a specific question about this device
(112 days)
Icare Finland Oy
The Icare HOME tonometer is a prescription device intended as an adjunct to the routine clinical monitoring of intraocular pressure (IOP) of adult patients.
The Icare HOME Tonometer is a home-use handheld, battery operated device. The Icare HOME tonometer technology is based on the previously cleared Icare tonometer model TA011 (K063873), which has been commercially distributed in the United States, Europe and many other countries worldwide. The measurement method, the measurement algorithm and technology of the two models are identical and both models use the same disposable probe tip. The Icare HOME tonometer utilizes the rebound method to measure intraocular pressure. A small (1.8 mm diameter), light (26.5 mg), sterile, single-use probe tip makes brief and gentle contact with the eye. The device measures the deceleration of the magnetized probe and the rebound time during contact with the eye and calculates the IOP from these parameters. Deceleration of the probe is slower at low IOP compared to high IOP. A single measurement sequence includes six measurements for both measurement modes. The probe moves to the cornea and returns to the neutral position during each of the six measurements. After the six measurements the tonometer calculates the final IOP and stores it with other information in the tonometer's memory, including date, time, eye identification (right or left) and measurement quality i.e., the standard deviation of the six individual measurements. The Icare HOME Tonometer can record over one thousand measurement results. The physician can transfer this recorded measurement information to a computer through a USB cable.
Here's an analysis of the provided text, extracting information related to acceptance criteria and the study proving the device meets them:
Device: Icare HOME Tonometer (K163343/S001)
Intended Use: Prescription device intended as an adjunct to the routine clinical monitoring of intraocular pressure (IOP) of adult patients.
1. Table of Acceptance Criteria and Reported Device Performance
The provided document doesn't explicitly state "acceptance criteria" in a tabulated format with pass/fail. Instead, it describes various tests and their "acceptable" outcomes. I've extrapolated these into a table based on the success statements. Note that some criteria are qualitative (e.g., "acceptable", "meets standards"), reflecting the regulatory language.
Aspect Tested | Acceptance Criteria (Implicitly Stated) | Reported Device Performance |
---|---|---|
Bench Performance - Accuracy (vs. Manometer) | Differences between Icare HOME tonometer and manometer values at each pressure should be less than +/- 3 mmHg. | Differences were less than +/- 3 mmHg across the range. |
Bench Performance - Precision (Standard Deviation) | Standard deviations and coefficients of variation should be consistently low. | Standard deviations and coefficients of variation for each Icare Home tonometer were consistently low (0-8%) across the measurement range, specifically 16 to |
Ask a specific question about this device
(118 days)
Icare Finland Oy
The Icare ic100 tonometer is intended to be used for the measurement of intraocular pressure of the human eye.
The Icare ic100 (TA011) tonometer is a hand-held, battery operated device which measures intraocular pressure (IOP) without the need for topical anesthesia. The Icare ic100 (TA011) tonometer is fundamentally the same as the predicate Icare tonometer model TA01i (cleared by FDA under K063873). The measurement method, the IOP measurement algorithm and rebound technology (including disposable probe) are identical for both models. The Icare ic100 (TA011) tonometer utilizes the rebound method to measure intraocular pressure. A small (1.8 mm diameter), light (26.5 mg), sterile, single-use probe makes brief and gentle contact with the eye. The tonometer measures the deceleration of the magnetized probe and the rebound time during contact with the eye and calculates the IOP from these parameters. Deceleration of the probe is slower at low IOP compared to high IOP.
A single measurement sequence includes six measurements. After the six measurements are completed, the tonometer calculates the final IOP and the result is provided on the display.
Here's a breakdown of the acceptance criteria and study information for the Icare ic100 tonometer based on the provided document:
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly state formal "acceptance criteria" with specific numerical targets. Instead, it focuses on demonstrating that the Icare ic100 performs comparably to its predicate device, the Icare TA01i. The core of the performance demonstration is that the operational principle, measurement algorithm, and rebound technology are identical.
Therefore, the "acceptance criteria" are implied to be substantially equivalent performance to the predicate device, particularly with regard to IOP measurement accuracy.
Performance Aspect | Acceptance Criteria (Implied) | Reported Device Performance (Icare ic100) |
---|---|---|
Measurement Method | Identical to predicate device | Identical to predicate device (IOP measurement algorithm unchanged, rebound technology identical) |
IOP Measurement Algorithm | Identical to predicate device | Identical to predicate device (K063873) |
Rebound Technology | Identical to predicate device | Identical to predicate device |
Range of Measurement | Same as predicate (7-50 mmHg) | Same as predicate (7-50 mmHg) |
Accuracy / Equivalence to Predicate | Performance comparable to Icare TA01i, validated according to ANSI Z80.10-2014 & IEC standards. | Verification tests carried out in accordance with ANSI Z80.10-2014 Ophthalmic Instruments - Tonometers confirmed that performance and safety aspects are comparable. |
Electrical Safety | Compliance with IEC 60601-1 | In compliance with IEC 60601-1 |
Electromagnetic Compatibility | Compliance with IEC 60601-1-2 | In compliance with IEC 60601-1-2 |
Software Life Cycle Processes | Compliance with IEC 62304 | Verified against the requirements of IEC 62304 |
2. Sample Size Used for the Test Set and Data Provenance
The document does not provide details on a specific "test set" and its sample size for evaluating the Icare ic100's primary measurement performance (IOP accuracy). The submission primarily relies on the equivalency of the measurement method, algorithm, and rebound technology to the predicate device.
It states that "Verification tests, where applicable, have been carried out in accordance with ANSI Z80.10-2014 Ophthalmic Instruments - Tonometers to confirm that the performance and safety aspects of the modified tonometer are comparable with the Icare TA01i." However, specific sample sizes (e.g., number of subjects, number of measurements) for these verification tests are not provided in this document.
Therefore, we cannot determine the sample size or data provenance (country, retrospective/prospective) from the provided text for a specific performance test set.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
This information is not provided in the document. Since the submission focuses on substantial equivalence to a predicate device with an identical measurement algorithm, it's possible that direct clinical studies establishing a new ground truth were not deemed necessary or details were not included in this summary. The ground truth for the predicate's calibration was stated to be "Goldmann reference tonometer data."
4. Adjudication Method for the Test Set
This information is not provided in the document.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and the Effect Size of Human Reader Improvement with AI vs Without AI Assistance
This device (Icare ic100 tonometer) is a standalone medical device for measuring intraocular pressure. It is not an AI-assisted diagnostic device, nor does it involve human readers interpreting images or data alongside AI. Therefore, an MRMC comparative effectiveness study involving AI assistance is not applicable and was not performed.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done
The entire device operates as a standalone algorithm without continuous human-in-the-loop intervention during the measurement process itself. The "algorithm only" performance is the device's performance. The document states:
- "The Icare ic100 (TA011) uses the same operating principle found in the predicate device and in all rebound type tonometers."
- "The IOP measurement algorithm is unchanged from the FDA cleared Icare tonometer model TA01i (K063873). Parameters from the signals produced by the probe momentarily contacting the eye (rebound parameters) are used to calculate an IOP-index. An embedded calibration table which was derived using Goldmann reference tonometer data is used to calculate an IOP value (in mmHg) based on the IOP-index."
This indicates that the standalone algorithm's performance is fundamental to the device's function, which is considered substantially equivalent to the predicate.
7. The Type of Ground Truth Used
For the calibration table embedded in the algorithm (which is identical to the predicate), the ground truth used was Goldmann reference tonometer data. This is explicitly stated: "An embedded calibration table which was derived using Goldmann reference tonometer data is used to calculate an IOP value (in mmHg) based on the IOP-index."
8. The Sample Size for the Training Set
The document states that the "IOP measurement algorithm is unchanged from the FDA cleared Icare tonometer model TA01i (K063873)" and that its calibration table was "derived using Goldmann reference tonometer data." However, the sample size for this derivation (training set for the calibration table) is not provided in this document.
9. How the Ground Truth for the Training Set was Established
The ground truth for the training set (from which the calibration table was derived for the predicate device's algorithm) was established using Goldmann reference tonometer data. The Goldmann applanation tonometer is considered the clinical gold standard for IOP measurement. This implies that measurements from the rebound tonometer were compared against concurrently measured Goldmann values to create the calibration.
Ask a specific question about this device
Page 1 of 1